RHYTHM PHARMACEUTICALS INC's ticker is RYTM and the CUSIP is 76243J105. A total of 128 filers reported holding RHYTHM PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.30 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,301,245 | +163.3% | 144,002 | +89.4% | 0.00% | – |
| Q2 2023 | $1,253,636 | -79.9% | 76,024 | -78.3% | 0.00% | -100.0% |
| Q1 2023 | $6,237,560 | +7.4% | 349,639 | +75.3% | 0.00% | 0.0% |
| Q4 2022 | $5,809,527 | +2564.9% | 199,503 | +954.3% | 0.00% | – |
| Q1 2022 | $218,000 | -13.1% | 18,923 | +60.8% | 0.00% | – |
| Q1 2021 | $251,000 | -4.6% | 11,770 | +33.2% | 0.00% | – |
| Q4 2020 | $263,000 | +24.1% | 8,838 | -7.0% | 0.00% | – |
| Q2 2020 | $212,000 | +15.8% | 9,505 | -20.9% | 0.00% | – |
| Q1 2020 | $183,000 | -51.5% | 12,021 | -0.3% | 0.00% | -100.0% |
| Q2 2018 | $377,000 | – | 12,056 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| NEA Management Company, LLC | 4,909,956 | $142,977,919 | 8.04% |
| Opaleye Management Inc. | 735,000 | $21,403,200 | 7.44% |
| Frazier Life Sciences Management, L.P. | 1,894,000 | $55,153,280 | 3.43% |
| RA Capital Management | 5,516,067 | $160,627,871 | 3.26% |
| Altium Capital Management LP | 170,000 | $4,950,400 | 2.52% |
| Samsara BioCapital, LLC | 345,293 | $10,054,932 | 2.16% |
| Rock Springs Capital Management LP | 1,760,865 | $51,276,389 | 1.23% |
| Parkman Healthcare Partners LLC | 157,862 | $4,596,941 | 1.22% |
| Baker Brothers Advisors | 6,354,608 | $185,046,185 | 1.11% |
| EAM Investors, LLC | 164,695 | $4,795,918 | 0.99% |